SCHEMBL6791013

SCHEMBL6791013

CCN1CC(=O)NC1=O.c1cc2cc-2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
EPHX2 P34913 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
CRBN Q96SW2 2/20 0.36
DDB1 Q16531 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
PGR P06401 3/20 0.35
LMNA P02545 1/20 0.34
DUT P33316 3/20 0.33
BRD4 O60885 1/20 0.33
CREBBP Q92793 1/20 0.33
GRM5 P41594 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LIPG Q9Y5X9 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL191785 0.83
Ammonia Solution, Strong SCHEMBL28261588 0.81 CRBN (0.46) MAPTEPHX2CRBNDDB1MEN1
Formaldehyde SCHEMBL8835722 0.79 CRBN (0.44) MAPTEPHX2CRBNDDB1MEN1
SCHEMBL11614855 0.79 MAPT (0.33) MAPTCRBN
Methylene Chloride SCHEMBL27573008 0.77 CRBN (0.43) MAPTEPHX2CRBNDDB1LMNA
SCHEMBL27918051 0.73 MAPT (0.47) MAPTCYP11B1CYP11B2MEN1KMT2A
Propionamide SCHEMBL27792957 0.71 CRBN (0.38) MAPTCRBNDDB1LMNAKDM4E
SCHEMBL14218702 0.69 EPHX2 (0.67) MAPTEPHX2MEN1KMT2AHSD17B10
SCHEMBL2001787 0.68 ENPP2 (0.57) EPHX2CRBNDDB1MEN1KMT2A
SCHEMBL193400 0.67 CRBN (0.50) MAPTEPHX2CRBNDDB1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 MAPT 4179/4885EPHX2 1247/4885CYP11B1 353/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 MAPT 4451/4885EPHX2 1144/4885CYP11B1 139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.